| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1464-5491.2005.01605.X |
| P698 | PubMed publication ID | 16026359 |
| P2093 | author name string | Leiter LA | |
| P2860 | cites work | Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. | Q51551544 |
| Addition of low-dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients. | Q51558091 | ||
| Assessing the potential for alpha-glucosidase inhibitors in prediabetic states. | Q51568023 | ||
| Beta-cell deterioration determines the onset and rate of progression of secondary dietary failure in type 2 diabetes mellitus: the 10-year follow-up of the Belfast Diet Study. | Q51570046 | ||
| Disproportionately elevated proinsulin levels reflect the degree of impaired B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus. | Q51571637 | ||
| Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin | Q22250892 | ||
| Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man | Q26776977 | ||
| Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group | Q27860882 | ||
| Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance | Q28186874 | ||
| Identifying the links between obesity, insulin resistance and beta-cell function: potential role of adipocyte-derived cytokines in the pathogenesis of type 2 diabetes | Q28218908 | ||
| Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group | Q29547282 | ||
| Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group | Q31976463 | ||
| Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group. | Q33864120 | ||
| Effect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetes. | Q33965301 | ||
| Effect of thiazolidinediones on body weight in patients with diabetes mellitus | Q34284191 | ||
| Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone | Q34324049 | ||
| PPARgamma agonists in type 2 diabetes: how far have we come in 'preventing the inevitable'? A review of the metabolic effects of rosiglitazone | Q34421542 | ||
| Beta-cell deterioration--prospects for reversal or prevention | Q34422778 | ||
| Cardiovascular risk reduction in diabetes: underemphasised and overdue. Messages from major trials | Q34494928 | ||
| Molecular insights into insulin action and secretion | Q34655565 | ||
| Free fatty acids in obesity and type 2 diabetes: defining their role in the development of insulin resistance and beta-cell dysfunction. | Q34655571 | ||
| The evolution of beta-cell dysfunction and insulin resistance in type 2 diabetes | Q34655580 | ||
| Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. October 7, 2003. | Q35603208 | ||
| Long-term glycaemic control with pioglitazone in patients with type 2 diabetes | Q35728336 | ||
| Fatty acid-induced beta cell apoptosis: a link between obesity and diabetes | Q35923385 | ||
| Insulin secretion in diabetes mellitus | Q40302183 | ||
| TNF-alpha and insulin resistance: summary and future prospects | Q40857239 | ||
| An increase in insulin sensitivity and basal beta-cell function in diabetic subjects treated with pioglitazone in a placebo-controlled randomized study. | Q42461955 | ||
| Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study | Q43670632 | ||
| The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus | Q43699554 | ||
| Ligands of peroxisome proliferator-activated receptor-gamma block activation of pancreatic stellate cells | Q43770515 | ||
| Clinical evidence of thiazolidinedione-induced improvement of pancreatic beta-cell function in patients with type 2 diabetes mellitus. | Q43902805 | ||
| Deteriorating beta-cell function in type 2 diabetes: a long-term model | Q44372257 | ||
| Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes | Q44393961 | ||
| Insulin, proinsulin, proinsulin:insulin ratio, and the risk of developing type 2 diabetes mellitus in women | Q44427238 | ||
| Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARgamma2 in the modulation of insulin secretion. | Q44660894 | ||
| Pioglitazone improves insulin secretory capacity and prevents the loss of beta-cell mass in obese diabetic db/db mice: Possible protection of beta cells from oxidative stress | Q44815359 | ||
| Rosiglitazone improves insulin sensitivity, glucose tolerance and ambulatory blood pressure in subjects with impaired glucose tolerance | Q44847730 | ||
| Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance | Q44916975 | ||
| Rosiglitazone prevents the onset of hyperglycaemia and proteinuria in the Zucker diabetic fatty rat. | Q48685670 | ||
| P433 | issue | 8 | |
| P921 | main subject | type 2 diabetes | Q3025883 |
| P304 | page(s) | 963-972 | |
| P577 | publication date | 2005-08-01 | |
| P1433 | published in | Diabetic Medicine | Q15758639 |
| P1476 | title | Beta-cell preservation: a potential role for thiazolidinediones to improve clinical care in Type 2 diabetes | |
| P478 | volume | 22 |
| Q36973815 | A cardiologist view of vascular disease in diabetes |
| Q64935296 | Analysis of Patents Issued in China for Antihyperglycemic Therapies for Type 2 Diabetes Mellitus. |
| Q47109286 | Beneficial Effects of Aerobic Exercise Training Combined with Rosiglitazone on Glucose Metabolism in Otsuka Long Evans Tokushima Fatty Rats |
| Q33999757 | Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial |
| Q37636165 | Exploration of the DPP-4 inhibitors with a focus on saxagliptin |
| Q38234927 | Insulin as a Bridge between Type 2 Diabetes and Alzheimer Disease - How Anti-Diabetics Could be a Solution for Dementia |
| Q37288741 | New drugs for type 2 diabetes mellitus: what is their place in therapy? |
| Q36918107 | Pharmacogenetics of thiazolidinedione therapy |
| Q37142044 | Pleiotropic effects of thiazolidinediones |
| Q30250347 | The current role of thiazolidinediones in diabetes management |
| Q35688754 | The fate of Beta-cells in type 2 diabetes and the possible role of pharmacological interventions |
| Q37142138 | Thiazolidinedione derivatives in diabetes and cardiovascular disease: an update |
| Q37505529 | Thiazolidinediones in prediabetes and early type 2 diabetes: what can be learned about that disease's pathogenesis |
| Q51158595 | Transaminase levels in the upper normal range are associated with oral hypoglycemic drug therapy failure in patients with type 2 diabetes. |
| Q36947018 | beta-cell function and anti-diabetic pharmacotherapy |
| Q39207056 | miRNA-30a-5p-mediated silencing of Beta2/NeuroD expression is an important initial event of glucotoxicity-induced beta cell dysfunction in rodent models. |
Search more.